Cargando…

Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study

INTRODUCTION: Although individualized target glycated hemoglobin (HbA(1c)) levels are recommended in older people with type 2 diabetes, studies report high levels of potential overtreatment. We aimed to investigate the proportion of older patients (aged ≥65 years) who potentially received an inappro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bongaerts, Brenda, Arnold, Suzanne V, Charbonnel, Bernard H, Chen, Hungta, Cooper, Andrew, Fenici, Peter, Gomes, Marilia, Ji, Linong, Khunti, Kamlesh, Kosiborod, Mikhail, Medina, Jesús, Nicolucci, Antonio, Shestakova, Marina, Shimomura, Iichiro, Tang, Fengming, Watada, Hirotaka, Rathmann, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098925/
https://www.ncbi.nlm.nih.gov/pubmed/33941550
http://dx.doi.org/10.1136/bmjdrc-2020-001585
_version_ 1783688502665281536
author Bongaerts, Brenda
Arnold, Suzanne V
Charbonnel, Bernard H
Chen, Hungta
Cooper, Andrew
Fenici, Peter
Gomes, Marilia
Ji, Linong
Khunti, Kamlesh
Kosiborod, Mikhail
Medina, Jesús
Nicolucci, Antonio
Shestakova, Marina
Shimomura, Iichiro
Tang, Fengming
Watada, Hirotaka
Rathmann, Wolfgang
author_facet Bongaerts, Brenda
Arnold, Suzanne V
Charbonnel, Bernard H
Chen, Hungta
Cooper, Andrew
Fenici, Peter
Gomes, Marilia
Ji, Linong
Khunti, Kamlesh
Kosiborod, Mikhail
Medina, Jesús
Nicolucci, Antonio
Shestakova, Marina
Shimomura, Iichiro
Tang, Fengming
Watada, Hirotaka
Rathmann, Wolfgang
author_sort Bongaerts, Brenda
collection PubMed
description INTRODUCTION: Although individualized target glycated hemoglobin (HbA(1c)) levels are recommended in older people with type 2 diabetes, studies report high levels of potential overtreatment. We aimed to investigate the proportion of older patients (aged ≥65 years) who potentially received an inappropriately intensive treatment (HbA(1c) level <7.0% (53.0 mmol/mol)) in a global study. Factors associated with intensive glycemic management and using glucose-lowering medications associated with a high risk of hypoglycemia (high-risk medications (insulin, sulfonylureas, and meglitinides)) were also assessed. RESEARCH DESIGN AND METHODS: DISCOVER is a 3-year observational study program of 15 992 people with type 2 diabetes initiating second-line glucose-lowering therapy in 38 countries. Data were collected at baseline (initiation of second-line therapy) and at 6, 12, and 24 months. Factors associated with an inappropriately intensive treatment or using high-risk medications were assessed using a hierarchical regression model. RESULTS: Of the 3344 older patients with baseline HbA(1c) data in our analytic cohort, 23.5% received inappropriate treatment intensification. Among those who had follow-up HbA(1c) data, 55.2%, 54.2%, and 53.5% were inappropriately tightly controlled at 6, 12, and 24 months, respectively, with higher proportions in high-income than in middle-income countries. The proportion of patients receiving high-risk medications was higher in middle-income countries than in high-income countries. Gross national income (per US$5000 increment) was associated with increased odds of inappropriately intensive treatment but with decreased odds of receiving high-risk medications. CONCLUSIONS: A large proportion of older DISCOVER patients received an inappropriately intensive glucose-lowering treatment across the 2 years of follow-up, with substantial regional variation. The use of high-risk medications in these patients is particularly concerning.
format Online
Article
Text
id pubmed-8098925
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-80989252021-05-18 Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study Bongaerts, Brenda Arnold, Suzanne V Charbonnel, Bernard H Chen, Hungta Cooper, Andrew Fenici, Peter Gomes, Marilia Ji, Linong Khunti, Kamlesh Kosiborod, Mikhail Medina, Jesús Nicolucci, Antonio Shestakova, Marina Shimomura, Iichiro Tang, Fengming Watada, Hirotaka Rathmann, Wolfgang BMJ Open Diabetes Res Care Epidemiology/Health services research INTRODUCTION: Although individualized target glycated hemoglobin (HbA(1c)) levels are recommended in older people with type 2 diabetes, studies report high levels of potential overtreatment. We aimed to investigate the proportion of older patients (aged ≥65 years) who potentially received an inappropriately intensive treatment (HbA(1c) level <7.0% (53.0 mmol/mol)) in a global study. Factors associated with intensive glycemic management and using glucose-lowering medications associated with a high risk of hypoglycemia (high-risk medications (insulin, sulfonylureas, and meglitinides)) were also assessed. RESEARCH DESIGN AND METHODS: DISCOVER is a 3-year observational study program of 15 992 people with type 2 diabetes initiating second-line glucose-lowering therapy in 38 countries. Data were collected at baseline (initiation of second-line therapy) and at 6, 12, and 24 months. Factors associated with an inappropriately intensive treatment or using high-risk medications were assessed using a hierarchical regression model. RESULTS: Of the 3344 older patients with baseline HbA(1c) data in our analytic cohort, 23.5% received inappropriate treatment intensification. Among those who had follow-up HbA(1c) data, 55.2%, 54.2%, and 53.5% were inappropriately tightly controlled at 6, 12, and 24 months, respectively, with higher proportions in high-income than in middle-income countries. The proportion of patients receiving high-risk medications was higher in middle-income countries than in high-income countries. Gross national income (per US$5000 increment) was associated with increased odds of inappropriately intensive treatment but with decreased odds of receiving high-risk medications. CONCLUSIONS: A large proportion of older DISCOVER patients received an inappropriately intensive glucose-lowering treatment across the 2 years of follow-up, with substantial regional variation. The use of high-risk medications in these patients is particularly concerning. BMJ Publishing Group 2021-05-03 /pmc/articles/PMC8098925/ /pubmed/33941550 http://dx.doi.org/10.1136/bmjdrc-2020-001585 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology/Health services research
Bongaerts, Brenda
Arnold, Suzanne V
Charbonnel, Bernard H
Chen, Hungta
Cooper, Andrew
Fenici, Peter
Gomes, Marilia
Ji, Linong
Khunti, Kamlesh
Kosiborod, Mikhail
Medina, Jesús
Nicolucci, Antonio
Shestakova, Marina
Shimomura, Iichiro
Tang, Fengming
Watada, Hirotaka
Rathmann, Wolfgang
Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
title Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
title_full Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
title_fullStr Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
title_full_unstemmed Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
title_short Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
title_sort inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global discover study
topic Epidemiology/Health services research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098925/
https://www.ncbi.nlm.nih.gov/pubmed/33941550
http://dx.doi.org/10.1136/bmjdrc-2020-001585
work_keys_str_mv AT bongaertsbrenda inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT arnoldsuzannev inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT charbonnelbernardh inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT chenhungta inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT cooperandrew inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT fenicipeter inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT gomesmarilia inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT jilinong inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT khuntikamlesh inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT kosiborodmikhail inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT medinajesus inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT nicolucciantonio inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT shestakovamarina inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT shimomuraiichiro inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT tangfengming inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT watadahirotaka inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy
AT rathmannwolfgang inappropriateintensificationofglucoseloweringtreatmentinolderpatientswithtype2diabetestheglobaldiscoverstudy